New migraine treatments could save $396 billion per year for US patients

24 May 2018
migraine_headache_patient_big

A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the USA could save $396 billion in indirect costs and avoid 374 million migraine days per year, according to a posting on the website of trade group Pharmaceutical Research and Manufacturers of America, by Samantha Dougherty, a senior director of policy and research at PhRMA.

For the one in six Americans who suffer from migraine, these new therapies, called calcitonin gene-related peptide (CGRP) inhibitors, offer hope as the first medicines developed specifically for the prevention of this disease. The study found CGRP inhibitors were associated with:

  • Fewer hours of lost productivity per year (more than 18 per year)
  • Reduced need for medicines that address the symptoms of migraine
  • Higher probability of full-time and part-time employment
  • Fewer ER visits per year

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical